Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
ClinicalTrials.gov ID NCT07260162 – Sponsor Institut Cancerologie de l'Ouest – ClinicalTrials.gov – NCT07260162
Publications ATO-101™
-
-
Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care
Rousseau, C.; Baumgartner, P.; Heymann, M.-F.; Taupin, M.; Geffroy, M.; Chatal, J.- F.; Gautier, G.; Allam, N.; Gaschet, J.; Eychenne, R.; Guérard, F.; Gestin, J.-F.; Varmenot, N.; Chérel, M. Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [ 211 At]At-anti-CA-IX Antibody (ATO- 101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care. Cancers 2025;17(7),1190. DOI: 10.3390/cancers17071190
-
PERTINENCE – 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer
ClinicalTrials.gov ID NCT04897763 – Sponsor Institut Cancerologie de l’Ouest – ClinicalTrials.gov – NCT04897763
-
PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer
ClinicalTrials.gov ID: NCT04897763 Sponsor: Institut de Cancérologie de l’Ouest (ICO) Collaborator: Atonco ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT04897763